blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News flashes

New version of the European Patent Register - SPC information for Unitary Patents.

2024-03-06

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2197438

EP2197438 - HETEROCYCLIC COMPOUNDS AS CRTH2 RECEPTOR ANTAGONISTS [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  20.05.2016
Database last updated on 17.07.2024
Most recent event   Tooltip13.10.2017Lapse of the patent in a contracting state
New state(s): BG, CY, HU, MT, TR		published on 15.11.2017  [2017/46]
Applicant(s)For all designated states
CSPC ZHONGQI PHARMACEUTICAL TECHNOLOGY (SHIJIAZHUANG) CO., LTD.
No. 226, Huanghe Street
Shijiazhuang
Hebei 050035 / CN
For all designated states
Centaurus BioPharma Co., Ltd.
Building No. 16
Tsinghua Science Park
Yuquan Wisdom Vale
Minzhuang Road No. 3, Haidian District
Beijing 100195 / CN
[2014/38]
Former [2010/25]For all designated states
Chemietek, Llc
Northeast Business Center 7301 E. 90th Street Suite 117
Indianapolis, IN 46256 / US
Inventor(s)01 / YUAN, Wei, W.
9000 Woodstock Way
Fishers IN 46037 / US
 [2010/25]
Representative(s)Moore, Michael Richard, et al
Keltie LLP
No.1 London Bridge
London SE1 9BA / GB
[2015/29]
Former [2010/25]Moore, Michael Richard, et al
Keltie Fleet Place House 2 Fleet Place
London EC4M 7ET / GB
Application number, filing date08838211.409.10.2008
[2010/25]
WO2008US79303
Priority number, dateUS20070998298P10.10.2007         Original published format: US 998298 P
[2010/25]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2009049021
Date:16.04.2009
Language:EN
[2009/16]
Type: A1 Application with search report 
No.:EP2197438
Date:23.06.2010
Language:EN
The application published by WIPO in one of the EPO official languages on 16.04.2009 takes the place of the publication of the European patent application.
[2010/25]
Type: B1 Patent specification 
No.:EP2197438
Date:15.07.2015
Language:EN
[2015/29]
Search report(s)International search report - published on:US16.04.2009
(Supplementary) European search report - dispatched on:EP14.09.2011
ClassificationIPC:C07D471/14, A61K31/437, A61P29/00
[2011/41]
CPC:
C07D471/14 (EP,KR,US); A61K31/437 (KR); A61P11/00 (EP);
A61P11/02 (EP); A61P11/06 (EP); A61P15/00 (EP);
A61P19/00 (EP); A61P19/10 (EP); A61P21/00 (EP);
A61P25/00 (EP); A61P25/04 (EP); A61P25/06 (EP);
A61P27/06 (EP); A61P27/10 (EP); A61P29/00 (EP);
A61P35/00 (EP); A61P35/04 (EP); A61P37/06 (EP);
A61P37/08 (EP); A61P43/00 (EP); A61P5/00 (EP);
A61P5/24 (EP); A61P7/02 (EP); A61P9/00 (EP);
A61P9/04 (EP); A61P9/08 (EP); A61P9/10 (EP);
A61P9/12 (EP) (-)
Former IPC [2010/25]A61K31/405
Designated contracting statesAT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MT,   NL,   NO,   PL,   PT,   RO,   SE,   SI,   SK,   TR [2015/29]
Former [2010/25]AT,  BE,  BG,  CH,  CY,  CZ,  DE,  DK,  EE,  ES,  FI,  FR,  GB,  GR,  HR,  HU,  IE,  IS,  IT,  LI,  LT,  LU,  LV,  MC,  MT,  NL,  NO,  PL,  PT,  RO,  SE,  SI,  SK,  TR 
TitleGerman:HETEROCYCLISCHE VERBINDUNGEN ALS CRTH2-REZEPTOR-ANTAGONISTEN[2010/25]
English:HETEROCYCLIC COMPOUNDS AS CRTH2 RECEPTOR ANTAGONISTS[2010/25]
French:COMPOSÉS HÉTÉROCYCLIQUES COMME ANTAGONISTES DU RÉCEPTEUR CRTH2[2015/08]
Former [2010/25]COMPOSÉS HÉTÉROCYCLIQUES SOUS FORME D'ANTAGONISTES DU RÉCEPTEUR CRTH2
Entry into regional phase04.05.2010National basic fee paid 
04.05.2010Search fee paid 
04.05.2010Designation fee(s) paid 
04.05.2010Examination fee paid 
Examination procedure04.05.2010Examination requested  [2010/25]
10.04.2012Amendment by applicant (claims and/or description)
12.02.2013Despatch of a communication from the examining division (Time limit: M04)
19.06.2013Reply to a communication from the examining division
29.01.2015Communication of intention to grant the patent
08.06.2015Fee for grant paid
08.06.2015Fee for publishing/printing paid
08.06.2015Receipt of the translation of the claim(s)
Divisional application(s)The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is  12.02.2013
Opposition(s)18.04.2016No opposition filed within time limit [2016/25]
Fees paidRenewal fee
29.10.2010Renewal fee patent year 03
27.10.2011Renewal fee patent year 04
30.10.2012Renewal fee patent year 05
10.12.2013Renewal fee patent year 06
31.10.2014Renewal fee patent year 07
Penalty fee
Additional fee for renewal fee
31.10.201306   M06   Fee paid on   10.12.2013
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU09.10.2008
AT15.07.2015
BE15.07.2015
BG15.07.2015
CY15.07.2015
CZ15.07.2015
DK15.07.2015
EE15.07.2015
FI15.07.2015
HR15.07.2015
IS15.07.2015
LT15.07.2015
LV15.07.2015
MC15.07.2015
MT15.07.2015
PL15.07.2015
RO15.07.2015
SI15.07.2015
SK15.07.2015
TR15.07.2015
LU09.10.2015
NO15.10.2015
GR16.10.2015
PT16.11.2015
[2017/39]
Former [2017/03]AT15.07.2015
BE15.07.2015
CZ15.07.2015
DK15.07.2015
EE15.07.2015
FI15.07.2015
HR15.07.2015
IS15.07.2015
LT15.07.2015
LV15.07.2015
MC15.07.2015
PL15.07.2015
RO15.07.2015
SI15.07.2015
SK15.07.2015
LU09.10.2015
NO15.10.2015
GR16.10.2015
PT16.11.2015
Former [2016/36]AT15.07.2015
CZ15.07.2015
DK15.07.2015
EE15.07.2015
FI15.07.2015
HR15.07.2015
IS15.07.2015
LT15.07.2015
LV15.07.2015
MC15.07.2015
PL15.07.2015
RO15.07.2015
SI15.07.2015
SK15.07.2015
LU09.10.2015
NO15.10.2015
GR16.10.2015
PT16.11.2015
Former [2016/31]AT15.07.2015
CZ15.07.2015
DK15.07.2015
EE15.07.2015
FI15.07.2015
HR15.07.2015
IS15.07.2015
LT15.07.2015
LV15.07.2015
MC15.07.2015
PL15.07.2015
RO15.07.2015
SK15.07.2015
LU09.10.2015
NO15.10.2015
GR16.10.2015
PT16.11.2015
Former [2016/28]AT15.07.2015
CZ15.07.2015
DK15.07.2015
EE15.07.2015
FI15.07.2015
HR15.07.2015
LT15.07.2015
LV15.07.2015
MC15.07.2015
PL15.07.2015
RO15.07.2015
SK15.07.2015
LU09.10.2015
NO15.10.2015
GR16.10.2015
PT16.11.2015
Former [2016/26]AT15.07.2015
CZ15.07.2015
DK15.07.2015
EE15.07.2015
FI15.07.2015
HR15.07.2015
LT15.07.2015
LV15.07.2015
PL15.07.2015
RO15.07.2015
SK15.07.2015
LU09.10.2015
NO15.10.2015
GR16.10.2015
PT16.11.2015
Former [2016/23]AT15.07.2015
CZ15.07.2015
DK15.07.2015
EE15.07.2015
FI15.07.2015
HR15.07.2015
LT15.07.2015
LV15.07.2015
PL15.07.2015
RO15.07.2015
SK15.07.2015
NO15.10.2015
GR16.10.2015
PT16.11.2015
Former [2016/22]AT15.07.2015
CZ15.07.2015
DK15.07.2015
EE15.07.2015
FI15.07.2015
HR15.07.2015
LT15.07.2015
LV15.07.2015
PL15.07.2015
NO15.10.2015
GR16.10.2015
PT16.11.2015
Former [2016/20]AT15.07.2015
DK15.07.2015
FI15.07.2015
HR15.07.2015
LT15.07.2015
LV15.07.2015
PL15.07.2015
NO15.10.2015
GR16.10.2015
PT16.11.2015
Former [2016/11]AT15.07.2015
FI15.07.2015
HR15.07.2015
LT15.07.2015
LV15.07.2015
PL15.07.2015
NO15.10.2015
GR16.10.2015
PT16.11.2015
Former [2016/10]FI15.07.2015
HR15.07.2015
LT15.07.2015
LV15.07.2015
PL15.07.2015
NO15.10.2015
GR16.10.2015
PT16.11.2015
Former [2016/09]FI15.07.2015
LT15.07.2015
LV15.07.2015
NO15.10.2015
GR16.10.2015
Former [2016/08]LT15.07.2015
NO15.10.2015
Former [2016/07]LT15.07.2015
Documents cited:Search[ID]WO2007019675  (MERCK FROSST CANADA LTD [CA], et al) [ID] 1-15 * page 5, line 14 - page 6, line 7; examples 1-3; claims 1-10 *;
 [E]WO2009140642  (AMIRA PHARMACEUTICALS INC [US], et al) [E] 1-15* examples 1-5; claims 1,20-61; tables 3-7 *
International search[X]US2005272756  (LEBLANC YVES [CA], et al);
 [A]US7144913  (WANG ZHAOYIN [CA], et al);
 [A]US2007191416  (FECHER ANJA [DE], et al)
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.